[Effect of low-dose dopamine adjuvant therapy on inflammatory factors and prognosis in preterm infants with necrotizing enterocolitis]

Zhongguo Dang Dai Er Ke Za Zhi. 2020 Feb;22(2):136-140. doi: 10.7499/j.issn.1008-8830.2020.02.010.
[Article in Chinese]

Abstract

Objective: To study the effect of low-dose dopamine adjuvant therapy on inflammatory factors and prognosis in preterm infants with necrotizing enterocolitis (NEC).

Methods: A total of 100 preterm infants with NEC from June 2017 to June 2019 were enrolled and divided into a dopamine treatment group and a conventional treatment group using a random number table, with 50 infants in each group. The infants in the conventional treatment group were given symptomatic treatment, and those in the dopamine treatment group were given low-dose dopamine adjuvant therapy in addition to the conventional treatment. ELISA was used to measure the levels of C-reactive protein (CRP), tumor necrosis factor-α (TNF-α), and interleukin-8 (IL-8). The two groups were compared in terms of time to relief of clinical symptoms, fasting time, treatment outcome, prognosis, and adverse reactions.

Results: Both groups had significant reductions in the levels of CRP, TNF-α, and IL-8 after treatment, and the dopamine treatment group had significantly lower levels of these markers than the conventional treatment group after treatment (P<0.05). Compared with the conventional treatment group, the dopamine treatment group had significantly shorter time to defecation improvement, time to relief of abdominal distension and diarrhea, and fasting time (P<0.05), a significantly higher response rate (P<0.05), and a significantly lower surgery rate (P<0.05). There were no significant differences in the mortality rate and incidence of adverse events between the two groups (P>0.05).

Conclusions: Low-dose dopamine adjuvant therapy can effectively improve the levels of inflammatory factors and clinical symptoms in preterm infants with NEC and has good safety, and therefore, it holds promise for clinical application.

目的: 探讨小剂量多巴胺辅助治疗对坏死性小肠结肠炎(NEC)早产儿炎症因子及预后的影响。

方法: 将2017年6月至2019年6月住院治疗的NEC早产儿100例,依据随机数字表法分为多巴胺治疗组(多巴胺组)和常规治疗组(常规组),每组50例。常规组给予常规对症治疗,多巴胺组在常规治疗基础上给予小剂量多巴胺辅助治疗。ELISA法检测两组C反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)、白介素-8(IL-8)水平;观察并记录两组患儿临床症状缓解时间、禁食时间、治疗疗效、预后及不良反应。

结果: 多巴胺组和常规组治疗后CRP、TNF-α、IL-8水平均明显低于治疗前,多巴胺组治疗后CRP、TNF-α、IL-8水平均明显低于常规组(P < 0.05);多巴胺组大便改善时间、腹胀及腹泻缓解时间、禁食时间均明显短于常规组(P < 0.05);多巴胺组治疗有效率明显高于常规组,手术率明显低于常规组(P < 0.05);两组病死率、不良反应发生率比较差异无统计学意义(P > 0.05)。

结论: 小剂量多巴胺辅助治疗可有效改善NEC早产儿炎症因子水平及临床症状,有利于提高患儿治疗疗效,且安全性好,值得临床推广。

MeSH terms

  • Dopamine
  • Enterocolitis, Necrotizing*
  • Humans
  • Infant
  • Infant, Newborn
  • Infant, Newborn, Diseases*
  • Infant, Premature
  • Prognosis

Substances

  • Dopamine